S. Saxena

发表

A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.

R. Amato, J. Zhai, J. Willis, 2012, Clinical genitourinary cancer.

Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax): A Phase 2 Trial

R. Amato, S. Saxena, S. Naylor, 2008, Journal of immunotherapy.

Long term follow-up of Thalidomide plus interleukin-2 based therapy in metastatic renal cell cancer patients

R. Amato, S. Saxena, Muhammad Khan, 2009 .

A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC)

R. Amato, S. Chiang, J. Willis, 2008 .

Rhizosphere fungi and nematodes of eggplant as influenced by oilcake amendments

Attaullah Khan, S. Saxena, M. W. Khan, 1974 .

The incidence of Alternaria species ID different cultivars of cabbage and cauliflower seeds

M. Khan, S. Saxena, Mohd. Abul-Fazal, 1994 .

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

R. Amato, J. Willis, S. Saxena, 2009, Cancer.

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

R. Amato, J. Willis, S. Saxena, 2008, Clinical Cancer Research.

Long term follow-up of Thalidomide plus Interleukin-2 based therapy in metastatic renal cell cancer patients Research

R. Amato, S. Saxena, Muhammad Khan, 2009 .

Lenalidomide Therapy for Metastatic Renal Cell Carcinoma

R. Amato, S. Saxena, J. Hernandez-McClain, 2008, American journal of clinical oncology.

Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.

Robert J. Amato, R. Amato, V. Melnikova, 2013, Urology.

Pilot study of rapamycin in patients with hormone-refractory prostate cancer.

R. Amato, S. Saxena, Robert J Amato, 2008, Clinical genitourinary cancer.

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α): A Phase 2 Trial

R. Amato, J. Willis, S. Saxena, 2009, Journal of immunotherapy.

A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy

R. Amato, J. Willis, S. Saxena, 2008 .

Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax [T]) administered + low dose interleukin-2 (IL-2): A phase II trial

R. Amato, J. Willis, S. Saxena, 2008 .

Phase II Trial Assessing Granulocyte-macrophage—Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments

R. Amato, S. Saxena, Mika Stepankiw, 2013, Cancer investigation.

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α): A Phase 2 Trial

R. Amato, J. Willis, S. Saxena, 2009, Journal of immunotherapy.

A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.

R. Amato, B. Teh, S. Saxena, 2009, Urologic oncology.